Open AccessRationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent
Author(s) -
Robert Gil,
Tomasz Pawłowski,
Jacek Legutko,
Maciej Lesiak,
Adam Witkowski,
Mariusz Gąsior,
Adam Kern,
Jacek Bil
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000015106
Subject(s) - medicine , sirolimus , randomized controlled trial , drug eluting stent , stent , drug , cardiology , pharmacology , restenosis
Coronary bifurcations are encountered in about 15% to 20% of percutaneous coronary interventions (PCIs). They are considered technically challenging and associated with worse clinical outcomes than nonbifurcation lesions. The BiOSS LIM C is a dedicated bifurcation balloon expandable stent made of cobalt-chromium alloy (strut thickness 70 μm) releasing sirolimus (1.4 μg/mm 2 ) from the surface of a biodegradable coating comprised of a copolymer of lactic and glycolic acids. Conclusion: The aim of the randomized, multicenter, open-label, controlled POLBOS III trial is to compare BiOSS LIM C with limus second-generation drug-eluting stents (DES) in the treatment of non-left main stem coronary bifurcations (ClinicalTrials.gov NCT03548272).